Business
SPECTRAL ANNOUNCES THIRD QUARTER 2010 RESULTS
SPECTRAL ANNOUNCES THIRD QUARTER 2010 RESULTS
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n Nov. 15, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nTORONTO, Nov. 15 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI), today announced its financial results for the third quarter ended\n September 30, 2010.\n\n\n"During the third quarter we continued our activities to implement the\n EUPHRATES trial. The clinical coordinating centre commenced operation,\n sites have been trained for EAA™/ Toraymyxin™ use, and selected sites\n have started enrolling patients," said Dr. Paul Walker, President and\n CEO of Spectral. "We are on target with the planned timeline for our\n EUPHRATES trial and anticipate that all 15 trial sites will be active\n and enrolling patients by early 2011."\n\n\nHighlights:\n\n\n\nInitiated EUPHRATES trial - the first theranostics trial, a combination\n of a therapeutic and a diagnostic, in the area of sepsis\n\n\nPresented Spectral's theranostic strategy at the Rodman & Renshaw Annual\n Global Investment Conference in New York on September 13, 2010\n\n\nContinued to qualify and train additional EUPHRATES trial sites\n\n\n\nFinancial Review\n\n\nFor the third quarter ended September 30, 2010, Spectral reported\n revenues of $722,000, compared to $815,000 for the corresponding period\n in 2009. For the nine months ended September 30, 2010, revenues were\n $2,148,000 compared to $2,433,000 for the same 2009 period. EAA™ diagnostic sales\n and royalty revenues from the Company's proprietary Troponin I products\n ...